Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects

Clin Neuropharmacol. 1991 Jun;14(3):256-61. doi: 10.1097/00002826-199106000-00010.


The capability of pravastatin and lovastatin, HMG-CoA reductase inhibitors likely to be taken chronically for hypercholesterolemia, to cross the blood-brain barrier was investigated in normal male volunteers. Lovastatin, which is lipophilic, was detected in cerebrospinal fluid (CSF) at concentrations that may have a pharmacologic effect. Pravastatin, which is hydrophilic, was not detected in CSF. It is concluded that pravastatin may have less potential for causing CNS-related side effects than lovastatin.

MeSH terms

  • Adult
  • Anticholesteremic Agents / cerebrospinal fluid*
  • Anticholesteremic Agents / pharmacokinetics
  • Blood-Brain Barrier
  • Heptanoic Acids / cerebrospinal fluid*
  • Heptanoic Acids / pharmacokinetics
  • Humans
  • Lovastatin / cerebrospinal fluid*
  • Lovastatin / pharmacokinetics
  • Male
  • Naphthalenes / cerebrospinal fluid*
  • Naphthalenes / pharmacokinetics
  • Pravastatin
  • Reference Values


  • Anticholesteremic Agents
  • Heptanoic Acids
  • Naphthalenes
  • Lovastatin
  • Pravastatin